MedTrace Logo

Recombinant H7 Hemagglutinin Influenza Vaccine Trial

NCT03038776 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 150

Last updated 2019-05-07

No results posted yet for this study

Summary

Recombinant H7 (rH7) vaccine has been shown to be poorly immunogenic in previous human clinical trials. This study will test approaches to improve the immunogenicity of H7 vaccine, namely use of a three dose regimen, use of a modified H7 HA sequence from which the Tregitope has been removed (rH7m), and inclusion of delta inulin adjuvant adjuvant in the vaccine

Conditions

  • Influenza, Avian

Interventions

BIOLOGICAL

Recombinant influenza hemagglutinin

Avian H7N9 influenza vaccine

Sponsors & Collaborators

  • Australian Respiratory and Sleep Medicine Institute

    collaborator OTHER

  • Vaxine Pty Ltd

    lead INDUSTRY

Principal Investigators

  • Dimitar Sajkov, MD, PhD · Flinders University/ARASMI

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2017-01-31
Primary Completion
2017-11-30
Completion
2019-05-31

Countries

  • Australia

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03038776 on ClinicalTrials.gov